Journey of a liquid biopsy

What is a liquid biopsy based test?

Certain lung cancer patients are not good candidates for tissue biopsy as this is an invasive procedure that carries risk. Liquid biopsy offers a non-invasive alternative for clinicians to identify clinically relevant biomarkers in patients to guide treatment decisions.

A liquid biopsy test looks for cancer cells or cell-free DNA (cfDNA) from a tumor that is circulating in the blood.1 Obtaining blood samples is less invasive compared to traditional tissue biopsies.

Opportunities for liquid biopsy

In non-small cell lung cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) testing is not performed in ~20% of eligible patients due to unavailable or insufficient tissue.2

Liquid biopsy can help overcome complications of a lung biopsy and is playing an increasing role as a companion diagnostics in cancer management.


Disease Management


  • Detection of Resistance
  • Treatment Decisions
  • Treatment Monitoring
  • Diagnosis of Recurrence


Liquid biopsy offers a non-invasive approach for personalised patient care.


Applications Today


  • Identify mutations
  • Treatment decisions (e.g. NSCLC)
  • Response to treatment (e.g. EGFR)


Applications Tomorrow


  • Treatment decisions for many cancers
  • Monitoring for recurrence
  • Screening for early diagnosis


  1., Accessed August 2, 2023.
  2. 2015 European Lung Cancer Conference (ELCC): Abstract LBA2_PR. Presented April 17, 2015